Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial
Marc‐Oliver Grimm, Christine Barbara Grün, Günter Niegisch, Martin Pichler, Florian Roghmann, Bernd J. Schmitz‐Dräger, Gustavo Baretton, Marc Schmitz, Christian Bolenz, Susan Foller, Katharina Leucht, Ulrike Schumacher, Martin Schostak, Johannes Meran, Wolfgang Loidl, Friedemann Zengerling
Topics & Concepts
NivolumabMedicineIpilimumabMetastatic Urothelial CarcinomaClinical endpointResponse Evaluation Criteria in Solid TumorsInternal medicineOncologyProgressive diseaseUrologyPopulationChemotherapyCarboplatinSurgeryBladder cancerClinical trialCancerImmunotherapyCisplatinUrothelial carcinomaEnvironmental healthBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis